drugset
drugset / Trial / NCT00004110

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

NCT00004110 ↗

Phase 2 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy plus etoposide in treating patients who have neuroblastoma.

Timeline

Start
1999-08
Primary completion
2004-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject 3F8 Monoclonal antibody — —
Subject Etoposide Small molecule — Oral
Subject Isotretinoin Other / unclassified — Oral

Indications

neuroblastoma